Success — FDA finally issues amalgam warning
- September 24, 2020, the U.S. Food and Drug Administration released its long-overdue safety communication on amalgam
- The FDA warns mercury fillings may adversely affect people in certain high-risk groups and should be avoided
- Groups identified as being at increased risk for harmful effects from dental mercury fillings include pregnant women and their developing fetuses, nursing women, women who are planning to become pregnant, infants and children under the age of 6, people with neurological diseases, impaired kidney function or heightened sensitivity to mercury or other amalgam components
- After years of pressure from Consumers for Dental Choice and its allies, the FDA finally agreed to reopen the amalgam issue, and now admits dental amalgam releases mercury vapor that can cause health problems in some individuals
- The FDA also advised against use of the misleading term “silver fillings,” and urges patients to discuss all dental filling options with their dentist
Just four weeks after we celebrated our 10th annual Mercury Awareness and Mercury-Free Dentistry Week, the U.S. Food and Drug Administration released a long-overdue safety communication on amalgam.
In an astounding about-face to its previous stance, the FDA issued a warning that mercury fillings may adversely affect pregnant women, children and other susceptible individuals, and should be avoided by these groups.
The safety communication1 was posted September 24, 2020, and with this, we have suddenly achieved an incredibly important goal that we’ve had our sights on for the last decade!
Goal Achieved: FDA Releases Amalgam Safety Communication
As noted in the FDA’s statement:2
“Today, the FDA is issuing updated recommendations concerning dental amalgam and potential risks to certain high-risk individuals that may be associated with these mercury-containing fillings …
The FDA has found that certain groups may be at greater risk for potential harmful health effects of mercury vapor released from the device [amalgam]. As a result, the agency is recommending certain high-risk groups avoid getting dental amalgam whenever possible and appropriate.”
Groups identified by the FDA as being at increased risk for harmful effects from dental mercury fillings include:
Pregnant women and their developing fetuses
Women who are planning to become pregnant
Nursing women and their newborns and infants
Children, especially those younger than 6
People with pre-existing neurological disease such as multiple sclerosis, Alzheimer’s disease or Parkinson’s disease
People with impaired kidney function
People with known heightened sensitivity (allergy) to mercury or other components of dental amalgam
FDA Admits Amalgam Dangers
After years of pressure from Consumers for Dental Choice and its allies, the FDA finally admits the unvarnished truth about amalgam, noting3 that “Dental amalgam is a mixture of mercury and a powdered alloy made up of silver, tin and copper” that “releases small amounts of mercury vapor over time.”
The FDA has found that certain groups may be at greater risk for potential harmful health effects of mercury vapor released from the device [amalgam]. As a result, the agency is recommending certain high-risk groups avoid getting dental amalgam whenever possible and appropriate.
The agency also admits there are “uncertainties” and risks associated with this mercury vapor release, especially for the high-risk groups listed. In particular, there is “the potential for mercury in dental amalgam to convert to other mercury compounds in the body,” and mercury could potentially accumulate in body fluids and tissues, resulting in “unintended health outcomes.”
“These uncertainties in the most vulnerable patients are why today we are recommending people who may be at high risk for adverse health effects of mercury exposure use non-mercury alternatives to dental amalgam, such as composite resins and glass ionomer cement fillings,” the FDA states.4
While the FDA downplays the importance of its changed recommendation by stressing that the benefits of dental amalgam likely “outweigh their risks for most patients,” this update is nothing short of monumental, and opens the door, finally, for the elimination of dental mercury for all patients in the U.S., as has been done in many other countries already.
I want to take this opportunity to thank all of you who have supported Consumers for Dental Choice during these past 10 years, as it is this organization’s unwavering dedication that has now borne fruit.
Consumers for Dental Choice Sued FDA — and Won
The FDA is legally required to classify — that is, issue a rule for — all medical devices, including dental amalgam. But for 30 years, FDA dodged its legal duty to classify amalgam.
Consumers for Dental Choice put an end to FDA's negligence when, in 2008, this dynamic nonprofit organization assembled plaintiffs and sued FDA, demanding that amalgam be classified. The judge agreed and told FDA to sit down with Consumers for Dental Choice to determine a deadline. FDA was compelled to commit to classifying amalgam by July 2009.
But when July 2009 came around, it was clear the FDA had not considered the science — especially the evidence of harm amalgam can cause vulnerable populations like children, pregnant women and breastfeeding mothers.
Its abysmal rule reflected this shortcoming, as it did not restrict the use of amalgam for these most vulnerable individuals. The rule did not even require that patients be told that amalgam is made of mercury. Nonetheless, FDA's 2009 rule did acknowledge that amalgam could be harmful, and that there was no proof of safety for the populations most susceptible to this toxin.
In response, Consumers for Dental Choice challenged FDA's rule, while simultaneously pursuing other opportunities to advance mercury-free dentistry, like defeating pro-mercury state dental boards, fighting for amalgam fact sheet laws for patients at the state level, and getting amalgam into the Minamata Convention on Mercury.
As Consumers for Dental Choice racked up win after win — regaining licenses for mercury-free dentists persecuted by state boards, gaining fact sheets to protect dental patients, achieving an amalgam reduction requirement in the Minamata Convention — the FDA’s rule was looking increasingly archaic.
Decade-Long Wait Is Over
Nearly a decade after the FDA issued its flawed amalgam rule, Consumers for Dental Choice launched a nonstop campaign focused on getting the FDA to move on amalgam.
They assembled an accomplished team of experts to approach the FDA, and in 2018, unveiled the “Chicago Declaration to End Mercury Use in the Dental Industry” at the University of Illinois School of Public Health.
This declaration, signed by more than 50 heavy-hitter environmental groups, called on the FDA "to bring its policies in line with the Federal Government as a whole and with its responsibilities under the Minamata Convention and to publicly advise a phase down of the use of mercury amalgams with the goal of phasing out entirely."
The declaration also called for the immediate ban on amalgam use in children, pregnant women and breastfeeding mothers. Working with key signatories to the “Chicago Declaration,” Consumers for Dental Choice were able to secure meetings with top officials at the FDA, during which they were able to submit scientific studies for the FDA to review.
The first sign of progress came with the FDA's September 2019 scientific review5 of amalgam, “Epidemiological Evidence on the Adverse Health Effects Reported in Relation to Mercury from Dental Amalgam,” which recognized that the elemental mercury in dental amalgam can convert inside the body into toxic methylmercury — the same type of mercury that the FDA warns about in fish.
The FDA also recognized bioaccumulative effects of mercury. Since patients are exposed to many sources of mercury — including high-mercury fish in their diets, occupational exposures and environmental mercury from waste incinerators — the mercury from amalgam could be the proverbial straw that breaks the camel's back.
FDA Reverses Stance on Amalgam
Consumers for Dental Choice also organized a strong showing of public support from you. Its online petition, which had nearly 50,000 signatures, was presented to the FDA in person at its first meeting with the agency. Many of you also submitted public comments on patient preferences to the FDA.
FDA was also made aware of the changes to amalgam rules in other parts of the world, such as amalgam phase-out dates set by the Philippines, Ireland, Slovakia, Finland, Nepal, Moldova, Czech Republic and New Caledonia, and the bans on amalgam use in children issued by the European Union, Vietnam and Tanzania.
Having finally reached the top of the FDA, Consumers for Dental Choice succeeded in persuading the agency to reopen and take another in-depth look at the amalgam policy.
A scientific advisory committee meeting — which included testimonies by 16 experts from the Children's Environmental Health Network, Tuskegee University, the International Indian Treaty Council, the Organic & Natural Health Association and the Connecticut Coalition for Environmental Justice, as well as city and county commissioners, a physician expert in environmental justice, a pharmacist specializing in toxicology and several attorneys — took place in November 2019.
You can see Consumers for Dental Choice's team and their colleagues in action in the video below, which features highlights of the advisory panel meeting.
Ultimately, the FDA advisory committee members recommended the agency provide information to patients about the risks of dental amalgam, especially for vulnerable populations. Many even agreed that the use of amalgam needs to end, which has been the goal of Consumers for Dental Choice all along.